A recent study led by GBI Research entitled “Cystic Fibrosis Therapeutics in Major Developed Markets 2019 – CFTR Modulators Initiate Drive Towards Personalized Treatment and Market Growth,” notes that the Cystic Fibrosis market will grow from $695.6 million in 2012 to near a $ 4.5 billion in 2019 in the world’s eight most developed countries.
This forecast represents a 30.4% growth in the Compound Annual Growth Rate (CAGR). GBI Research believes that new treatments capable of changing the disease’s mechanisms of action will ultimately contribute to a substantial growth rate. While there will be market loss from expiring patents, new drug products in the pipeline will compensate, leading to growth.
Considering the performance of the first Cystic Fibrosis Transmembrane Conductance Regulators (CFTR) modulator on the market, Kalydeco, it’s possible to assess that new therapies will hit the market with a substantial impact. Kalydeco, available since 2012, heavily influenced the CF market’s value, even though it is effective in only a very limited proportion of CF patients. It is expected that new therapies, like Lumacaftor or Ataluren, applicable to larger patient populations, will add potentially greater impact to the overall market value.
CFTRs were the first therapies to treat the underlying causes of cystic fibrosis instead of just the symptoms. Yet, medication to control the symptoms will still be needed. The antibiotics segment will be a competitive sector as well, according to GBI’s predictions.
In order to compile data and conclusions, GBI assessed the efficacy and safety of existing treatments and which gaps need to be filled, analyzed the market taking into account total and treated populations, projected the CF market considering the existing and future products and analyzed strategic consolidations.